CoChat
Sign Up
Cited by 375Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 177 of the 181 references it cites were found in a registry or an index.

American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm—2023 update

Samson, Susan L., Vellanki, Priyathama, Blonde, Lawrence, Christofides, Elena A., Galindo, Rodolfo J., Hirsch, Irl B., Isaacs, Scott D., Izuora, Kenneth E., Low Wang, Cecilia C., Twining, Christine L., Umpierrez, Guillermo E., Valencia, Willy Marcos·2023·Endocrine Practice
DOI 10.1016/j.eprac.2023.02.001
Open this paper in CoChat — free account

Abstract

OBJECTIVE This consensus statement provides (1) visual guidance in concise graphic algorithms to assist with clinical decision-making of health care professionals in the management of persons with type 2 diabetes mellitus to improve patient care and (2) a summary of details to support the visual guidance found in each algorithm. METHODS The American Association of Clinical Endocrinology (AACE) selected a task force of medical experts who updated the 2020 AACE Comprehensive Type 2 Diabetes Management Algorithm based on the 2022 AACE Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan and consensus of task force authors. RESULTS This algorithm for management of persons with type 2 diabetes includes 11 distinct sections: (1) Principles for the Management of Type 2 Diabetes; (2) Complications-Centric Model for the Care of Persons with Overweight/Obesity; (3) Prediabetes Algorithm; (4) Atherosclerotic Cardiovascular Disease Risk Reduction Algorithm: Dyslipidemia; (5) Atherosclerotic Cardiovascular Disease Risk Reduction Algorithm: Hypertension; (6) Complications-Centric Algorithm for Glycemic Control; (7) Glucose-Centric Algorithm for Glycemic Control; (8) Algorithm for Adding/Intensifying Insulin; (9) Profiles of Antihyperglycemic Medications; (10) Profiles of Weight-Loss Medications (new); and (11) Vaccine Recommendations for Persons with Diabetes Mellitus (new), which summarizes recommendations from the Advisory Committee on Immunization Practices of the U.S. Centers for Disease Control and Prevention. CONCLUSIONS Aligning with the 2022 AACE diabetes guideline update, this 2023 diabetes algorithm update emphasizes lifestyle modification and treatment of overweight/obesity as key pillars in the management of prediabetes and diabetes mellitus and highlights the importance of appropriate management of atherosclerotic risk factors of dyslipidemia and hypertension. One notable new theme is an emphasis on a complication-centric approach, beyond glucose levels, to frame decisions regarding first-line pharmacologic choices for the treatment of persons with diabetes. The algorithm also includes access/cost of medications as factors related to health equity to consider in clinical decision-making.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.eprac.2023.02.001

Cites

177 of 177 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 2

  1. 2008, Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, 358, 2545
  2. Mechanick, 2019, Endocr Pract, 25, 1346

Cited by

Sorted by citations

See all 375

Related

See all

Metadata

Authors
Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., Umpierrez, G. E., & Valencia, W. M.
Affiliations
  • Mayo Clinic (US)
  • Grady Memorial Hospital (US)
  • Ochsner Health System (US)
  • Indiana University Columbus (US)
  • University of Miami (US)
  • University of Washington (US)
  • Emory University (US)
  • University of Nevada, Las Vegas (US)
  • Maine Medical Center (US)
  • Cleveland Clinic (US)
ORCID
Venue
Endocrine Practice
Publisher
Elsevier BV
Published
2023-05
Volume
29
Issue
5
Pages
305-340
ISSN
1530-891X (ISSN-L)
DOI
10.1016/j.eprac.2023.02.001
OpenAlex
W4372214811
Semantic Scholar
066a5bccabf1b093084ed77c43509daa1c94c321
Cited by
375
References
181
Citations by year
2026: 62 · 2025: 150 · 2024: 124 · 2023: 38
FWCI
76.07
Type
journal article
Language
en
Update notices
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Endocrine Practice (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (K23DK123384)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes, prediabetes, glycemic control, dyslipidemia, hypertension, insulin intensification, antihyperglycemic medications, anti-obesity drugs, obesity, lifestyle modification, health equity
MeSH terms
Endocrinologists, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Endocrinology, Glucose, Humans, Hypertension, Obesity, Prediabetic State, United States, Dyslipidemias, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review